<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177722</url>
  </required_header>
  <id_info>
    <org_study_id>A3L24</org_study_id>
    <secondary_id>UTN: U1111-1111-5801</secondary_id>
    <nct_id>NCT01177722</nct_id>
  </id_info>
  <brief_title>A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants</brief_title>
  <official_title>Lot-to-Lot Consistency Study of DTaP-IPV-Hep B-PRP-T Vaccine Administered at 2-4-6 Months of Age in Healthy Latin American Infants Concomitantly With Prevenar™ and Rotarix™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to generate immunogenicity and safety data of an investigational
      hexavalent DTaP-IPV-Hep B-PRP-T vaccine compared to a control vaccine, Infanrix hexa™ when
      given along with Prevenar™ and Rotarix™ vaccines.

      Primary Objectives:

        -  To demonstrate the equivalence of immunogenicity of 3 lots of DTaP-IPV-Hep B-PRP-T
           vaccine 1 month after a 3-dose primary series (2, 4 and 6 months) when given with
           Prevenar™ and Rotarix™, in terms of immunoresponses.

        -  To demonstrate the non-inferiority of the hexavalent DTaP-IPV-Hep B-PRP-T vaccine to the
           licensed hexavalent Infanrix hexa vaccine when given with Prevenar™ and Rotarix™.

      Secondary Objectives:

        -  To describe in each group the immunogenicity parameters for all antigens for each
           vaccine

        -  To assess the safety profile in terms of solicited and unsolicited adverse events and
           serious adverse events in each group for each vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each participant will receive 3 doses of 1 of 3 lots of the investigational hexavalent
      vaccine or the control vaccine, Infanrix hexa™, administered with Prevenar™ at 2, 4, and 6
      months of age and Rotarix™ at 2 and 4 months of age.

      All participants will be monitored for safety for 6 months after the last injection of the
      primary vaccination series.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Anti-Hepatitis B Before and After 3 Dose Primary Vaccination With Either DTaP-IPV-Hep B-PRP~T Batch A, B, or C, or Infanrix Hexa™</measure>
    <time_frame>Day 0 (pre-vaccination) Dose 1 and 30 days post-vaccination</time_frame>
    <description>Antibodies against Hepatitis B (Hep B) were measured by chemiluminescence detection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Seroprotection or Vaccine Response After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccine</measure>
    <time_frame>30 Days post-dose 3</time_frame>
    <description>Seroprotection was defined as titers ≥ 0.01 IU/mL for Diphtheria (D) and Tetanus (T); ≥ 10 IU/mL for Hep B; ≥ 0.15 µg/mL for PRP, and ≥ 8 (1/dil) for Poliovirus. Vaccine response for PT and FHA were defined as a titer ≥ lower limit of quantitation (LLOQ) in initially seronegative participants, or at least persistence (post-vaccination titer ≥ pre-vaccination titer) in initially seropositive subjects (titer ≥ LLOQ).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Antibodies After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) and 30 days post-dose 3</time_frame>
    <description>Antibodies were measured by toxin neutralization test for Diphtheria (D); enzyme-linked immunosorbent assay (ELISA) for Tetanus (T), Pertussis toxoid (PT), and Filamentous hemagglutinin (FHA); neutralization assay for Poliovirus types 1, 2, and 3; chemiluminescence detection for Hepatitis B (Hep B), and Farr type radioimmunoassay for Haemophilus influenza type b (PRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting at Least One Solicited Injection Site (Study Vaccine) or Systemic Reactions After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccine</measure>
    <time_frame>Day 0 up to 7 after each dose</time_frame>
    <description>Solicited Injection Site Reactions: Pain, Erythema, and Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia,and Irritability. Grade 3 was defined as: Pain, cries when injected limb is moved or movement of the limb is reduced; Erythema and Swelling, ≥ 5 cm; Pyrexia, (Temperature) ≥ 39.6°C; Vomiting, ≥ 6 episodes/24 hours or requiring parenteral hydration; Crying, &gt; 3 hours; Somnolence, sleeping most of time or difficult to wake up; Anorexia, refuses ≥ 3 feed/meals or refuses most feeds/meals; and Irritability, inconsolable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting at Least One Solicited Injection Site Reaction at the Prevenar Injection Site After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Vaccine</measure>
    <time_frame>Day 0 up to 7 post each vaccination</time_frame>
    <description>Solicited Injection Site Reactions: Pain, Erythema, and Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability. Grade 3 was defined as: Pain, cries when injected limb is moved or movement of the limb is reduced; Erythema and Swelling, ≥ 5 cm; Pyrexia (Temperature), ≥ 39.6ºC; Vomiting, ≥ 6 episodes/24 hours or requiring parenteral hydration; Crying, &gt; 3 hours; Somnolence, sleeping most of time or difficult to wake up; Anorexia, refuses ≥ 3 feed/meals or refuses most feeds/meals; and Irritability, inconsolable.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1375</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Whooping Cough</condition>
  <condition>Hepatitis B</condition>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Group 1: DTaP-IPV-Hep B-PRP-T (Lot A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: DTaP-IPV-Hep B-PRP-T (Lot B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: DTaP-IPV-Hep B-PRP-T (Lot C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-Hep B-PRP-T Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 1: DTaP-IPV-Hep B-PRP-T (Lot A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-Hep B-PRP-T Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 2: DTaP-IPV-Hep B-PRP-T (Lot B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-Hep B-PRP-T Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 3: DTaP-IPV-Hep B-PRP-T (Lot C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-Hep B-IPV vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 4: Active Control</arm_group_label>
    <other_name>Infanrix hexa™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Two month old infants (55 to 65 days old) on the day of inclusion.

          -  Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg.

          -  Informed consent form signed by one or both parents or by the legally acceptable
             representative as per local requirements.

          -  Able to attend all scheduled visits and to comply with all trial procedures.

          -  Received Hepatitis B and Bacille de Calmette-Guérin (BCG) vaccines between birth and
             one month of life in agreement with the national immunization calendar.

        Exclusion Criteria :

          -  Participation in another clinical trial in the 4 weeks preceding the first trial
             vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy,
             or long-term systemic corticosteroid therapy.

          -  Known systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the trial vaccine or a vaccine containing the same
             substances.

          -  Chronic illness at a stage that could interfere with trial conduct or completion, in
             the opinion of the Investigator.

          -  Blood or blood-derived products received since birth that might interfere with the
             assessment of the immune response.

          -  Any vaccination before trial vaccination (except Hepatitis B and Bacille de Calmette
             Guérin given at birth).

          -  Any planned vaccination until 1 month after the last trial vaccination (except the
             study vaccines, rotavirus and pneumococcal conjugated vaccines).

          -  Documented history of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus
             influenzae type b or Hepatitis B infection(s) (confirmed either clinically,
             serologically or microbiologically).

          -  Previous vaccination against pertussis, tetanus, diphtheria, poliomyelitis, or
             Haemophilus influenzae type b infections.

          -  Known personal or maternal history of Human Immunodeficiency Virus (HIV), hepatitis B
             surface antigen (HBsAg) or hepatitis C seropositivity.

          -  Known coagulopathy, thrombocytopenia or a bleeding disorder preceding inclusion
             contraindicating intramuscular (IM) vaccination.

          -  History of seizures or encephalopathy.

          -  Febrile illness (temperature ≥ 38.0°C), or moderate or severe acute illness/infection
             on the day of inclusion, according to the Investigator judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Days</minimum_age>
    <maximum_age>65 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San José de Costa Rica</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Costa Rica</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <results_first_submitted>February 22, 2014</results_first_submitted>
  <results_first_submitted_qc>April 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2014</results_first_posted>
  <last_update_submitted>April 3, 2014</last_update_submitted>
  <last_update_submitted_qc>April 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Whooping cough</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Diphtheria-Tetanus-acellular Pertussis Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 03 August 2010 to 23 November 2010 in 2 clinical centers in Columbia and 1 clinical center in Costa Rica.</recruitment_details>
      <pre_assignment_details>A total of 1375 participants who met all inclusion criteria and none of the exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DTap-IPV-Hep B-PRP~T Batch A</title>
          <description>Participants received a 3-dose primary series of vaccinations with Batch A of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
        <group group_id="P2">
          <title>DTaP-IPV-Hep B-PRP~T Batch B</title>
          <description>Participants received a 3-dose primary series of vaccinations with Batch B of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
        <group group_id="P3">
          <title>DTaP-IPV-Hep B-PRP~T Batch C</title>
          <description>Participants received a 3-dose primary series of vaccinations with Batch C of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
        <group group_id="P4">
          <title>Infanrix Hexa</title>
          <description>Participants received a 3-dose primary series of vaccinations with the licensed Infanrix hexa™, with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="344">A Batch B participant got Batch A vaccine data analyses was according to actual vaccine administered</participants>
                <participants group_id="P2" count="344">A randomized participant got Batch A vaccine, analyses was according to actual vaccine administered.</participants>
                <participants group_id="P3" count="342"/>
                <participants group_id="P4" count="345"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="331"/>
                <participants group_id="P2" count="334"/>
                <participants group_id="P3" count="333"/>
                <participants group_id="P4" count="338"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DTap-IPV-Hep B-PRP~T Batch A</title>
          <description>Participants received a 3-dose primary series of vaccinations with Batch A of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
        <group group_id="B2">
          <title>DTaP-IPV-Hep B-PRP~T Batch B</title>
          <description>Participants received a 3-dose primary series of vaccinations with Batch B of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
        <group group_id="B3">
          <title>DTaP-IPV-Hep B-PRP~T Batch C</title>
          <description>Participants received a 3-dose primary series of vaccinations with Batch C of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Infanrix Hexa</title>
          <description>Participants received a 3-dose primary series of vaccinations with the licensed Infanrix hexa™, with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="344"/>
            <count group_id="B2" value="344"/>
            <count group_id="B3" value="342"/>
            <count group_id="B4" value="345"/>
            <count group_id="B5" value="1375"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="344"/>
                    <measurement group_id="B2" value="344"/>
                    <measurement group_id="B3" value="342"/>
                    <measurement group_id="B4" value="345"/>
                    <measurement group_id="B5" value="1375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="3.49"/>
                    <measurement group_id="B2" value="58.7" spread="3.25"/>
                    <measurement group_id="B3" value="58.5" spread="3.16"/>
                    <measurement group_id="B4" value="58.7" spread="3.31"/>
                    <measurement group_id="B5" value="58.7" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="156"/>
                    <measurement group_id="B5" value="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="190"/>
                    <measurement group_id="B4" value="189"/>
                    <measurement group_id="B5" value="741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="233"/>
                    <measurement group_id="B4" value="233"/>
                    <measurement group_id="B5" value="933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Costa Rica</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B5" value="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Anti-Hepatitis B Before and After 3 Dose Primary Vaccination With Either DTaP-IPV-Hep B-PRP~T Batch A, B, or C, or Infanrix Hexa™</title>
        <description>Antibodies against Hepatitis B (Hep B) were measured by chemiluminescence detection.</description>
        <time_frame>Day 0 (pre-vaccination) Dose 1 and 30 days post-vaccination</time_frame>
        <population>GMTs were assessed in all subjects who did not have any protocol violation that might interfere with primary criteria evaluation (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>DTap-IPV-Hep B-PRP~T Batch A</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch A of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-Hep B-PRP~T Batch B</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch B of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-Hep B-PRP~T Batch C</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch C of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa</title>
            <description>Participants received a 3-dose primary series of vaccinations with the licensed Infanrix hexa™, with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Anti-Hepatitis B Before and After 3 Dose Primary Vaccination With Either DTaP-IPV-Hep B-PRP~T Batch A, B, or C, or Infanrix Hexa™</title>
          <description>Antibodies against Hepatitis B (Hep B) were measured by chemiluminescence detection.</description>
          <population>GMTs were assessed in all subjects who did not have any protocol violation that might interfere with primary criteria evaluation (Per-Protocol Population).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="310"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Hep B Pre-dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" lower_limit="3.50" upper_limit="4.61"/>
                    <measurement group_id="O2" value="4.07" lower_limit="3.58" upper_limit="4.62"/>
                    <measurement group_id="O3" value="4.93" lower_limit="4.20" upper_limit="5.79"/>
                    <measurement group_id="O4" value="4.30" lower_limit="3.68" upper_limit="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hep B Post-dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3048" lower_limit="2672" upper_limit="3476"/>
                    <measurement group_id="O2" value="2801" lower_limit="2467" upper_limit="3181"/>
                    <measurement group_id="O3" value="3202" lower_limit="2794" upper_limit="3668"/>
                    <measurement group_id="O4" value="2766" lower_limit="2466" upper_limit="3102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Seroprotection or Vaccine Response After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccine</title>
        <description>Seroprotection was defined as titers ≥ 0.01 IU/mL for Diphtheria (D) and Tetanus (T); ≥ 10 IU/mL for Hep B; ≥ 0.15 µg/mL for PRP, and ≥ 8 (1/dil) for Poliovirus. Vaccine response for PT and FHA were defined as a titer ≥ lower limit of quantitation (LLOQ) in initially seronegative participants, or at least persistence (post-vaccination titer ≥ pre-vaccination titer) in initially seropositive subjects (titer ≥ LLOQ).</description>
        <time_frame>30 Days post-dose 3</time_frame>
        <population>Seroprotection and vaccine response were assessed in all subjects who did not have any protocol violation that might interfere with primary criteria evaluation (Per Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>DTap-IPV-Hep B-PRP~T Batch A</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch A of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-Hep B-PRP~T Batch B</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch B of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-Hep B-PRP~T Batch C</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch C of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa</title>
            <description>Participants received a 3-dose primary series of vaccinations with the licensed Infanrix hexa™, with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroprotection or Vaccine Response After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccine</title>
          <description>Seroprotection was defined as titers ≥ 0.01 IU/mL for Diphtheria (D) and Tetanus (T); ≥ 10 IU/mL for Hep B; ≥ 0.15 µg/mL for PRP, and ≥ 8 (1/dil) for Poliovirus. Vaccine response for PT and FHA were defined as a titer ≥ lower limit of quantitation (LLOQ) in initially seronegative participants, or at least persistence (post-vaccination titer ≥ pre-vaccination titer) in initially seropositive subjects (titer ≥ LLOQ).</description>
          <population>Seroprotection and vaccine response were assessed in all subjects who did not have any protocol violation that might interfere with primary criteria evaluation (Per Protocol Population).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="310"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Diphtheria (N = 310, 310, 312, 315)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="310"/>
                    <measurement group_id="O3" value="312"/>
                    <measurement group_id="O4" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus (N = 311, 310, 311, 314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="310"/>
                    <measurement group_id="O3" value="311"/>
                    <measurement group_id="O4" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT (N = 308, 309, 308, 312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304"/>
                    <measurement group_id="O2" value="299"/>
                    <measurement group_id="O3" value="299"/>
                    <measurement group_id="O4" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (N = 306, 306, 304, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306"/>
                    <measurement group_id="O2" value="305"/>
                    <measurement group_id="O3" value="303"/>
                    <measurement group_id="O4" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 (N = 310, 309, 308, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="309"/>
                    <measurement group_id="O3" value="308"/>
                    <measurement group_id="O4" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 (N = 309, 309, 307, 312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="309"/>
                    <measurement group_id="O3" value="307"/>
                    <measurement group_id="O4" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 (N = 310, 309, 307, 312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="309"/>
                    <measurement group_id="O3" value="307"/>
                    <measurement group_id="O4" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hep B (N = 312, 310, 312, 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="310"/>
                    <measurement group_id="O3" value="310"/>
                    <measurement group_id="O4" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP (N = 312, 310, 312, 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299"/>
                    <measurement group_id="O2" value="298"/>
                    <measurement group_id="O3" value="287"/>
                    <measurement group_id="O4" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Antibodies After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccine</title>
        <description>Antibodies were measured by toxin neutralization test for Diphtheria (D); enzyme-linked immunosorbent assay (ELISA) for Tetanus (T), Pertussis toxoid (PT), and Filamentous hemagglutinin (FHA); neutralization assay for Poliovirus types 1, 2, and 3; chemiluminescence detection for Hepatitis B (Hep B), and Farr type radioimmunoassay for Haemophilus influenza type b (PRP).</description>
        <time_frame>Day 0 (pre-vaccination) and 30 days post-dose 3</time_frame>
        <population>GMTs were assessed in all subjects who did not have any protocol violation that might interfere with primary criteria evaluation (Per Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>DTap-IPV-Hep B-PRP~T Batch A</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch A of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-Hep B-PRP~T Batch B</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch B of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-Hep B-PRP~T Batch C</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch C of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa™</title>
            <description>Participants received a 3-dose primary series of vaccinations with the licensed Infanrix hexa™, with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Antibodies After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccine</title>
          <description>Antibodies were measured by toxin neutralization test for Diphtheria (D); enzyme-linked immunosorbent assay (ELISA) for Tetanus (T), Pertussis toxoid (PT), and Filamentous hemagglutinin (FHA); neutralization assay for Poliovirus types 1, 2, and 3; chemiluminescence detection for Hepatitis B (Hep B), and Farr type radioimmunoassay for Haemophilus influenza type b (PRP).</description>
          <population>GMTs were assessed in all subjects who did not have any protocol violation that might interfere with primary criteria evaluation (Per Protocol Population).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="310"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Diphtheria Pre-dose 1 (N= 312, 308, 311, 315)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.599" lower_limit="0.513" upper_limit="0.699"/>
                    <measurement group_id="O2" value="0.596" lower_limit="0.505" upper_limit="0.703"/>
                    <measurement group_id="O3" value="0.641" lower_limit="0.547" upper_limit="0.752"/>
                    <measurement group_id="O4" value="0.630" lower_limit="0.530" upper_limit="0.749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Post-dose 3 (N=310, 310, 312, 315)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.252" lower_limit="0.224" upper_limit="0.285"/>
                    <measurement group_id="O2" value="0.279" lower_limit="0.247" upper_limit="0.316"/>
                    <measurement group_id="O3" value="0.228" lower_limit="0.201" upper_limit="0.260"/>
                    <measurement group_id="O4" value="0.240" lower_limit="0.214" upper_limit="0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Post-dose 3 (N = 311, 310, 311, 314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" lower_limit="1.54" upper_limit="1.78"/>
                    <measurement group_id="O2" value="1.55" lower_limit="1.43" upper_limit="1.68"/>
                    <measurement group_id="O3" value="1.45" lower_limit="1.33" upper_limit="1.59"/>
                    <measurement group_id="O4" value="1.80" lower_limit="1.69" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT Pre-dose 1 (N = 308, 309, 310, 314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" lower_limit="2.65" upper_limit="3.45"/>
                    <measurement group_id="O2" value="3.50" lower_limit="3.03" upper_limit="4.04"/>
                    <measurement group_id="O3" value="3.54" lower_limit="3.10" upper_limit="4.05"/>
                    <measurement group_id="O4" value="3.11" lower_limit="2.70" upper_limit="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT Post-dose 3 (N = 312, 310, 311, 314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" lower_limit="96.1" upper_limit="108"/>
                    <measurement group_id="O2" value="103" lower_limit="95.9" upper_limit="110"/>
                    <measurement group_id="O3" value="102" lower_limit="95.0" upper_limit="110"/>
                    <measurement group_id="O4" value="98.9" lower_limit="92.3" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Pre-dose 1(N = 307, 307, 307, 312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" lower_limit="4.77" upper_limit="6.02"/>
                    <measurement group_id="O2" value="5.66" lower_limit="5.01" upper_limit="6.39"/>
                    <measurement group_id="O3" value="5.76" lower_limit="5.12" upper_limit="6.49"/>
                    <measurement group_id="O4" value="5.13" lower_limit="4.61" upper_limit="5.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Post-dose 3 (N=311, 309, 310, 315)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" lower_limit="174" upper_limit="199"/>
                    <measurement group_id="O2" value="175" lower_limit="163" upper_limit="188"/>
                    <measurement group_id="O3" value="183" lower_limit="171" upper_limit="197"/>
                    <measurement group_id="O4" value="118" lower_limit="110" upper_limit="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 Post-dose 3 (N = 310, 309, 308, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="755" lower_limit="674" upper_limit="847"/>
                    <measurement group_id="O2" value="655" lower_limit="580" upper_limit="739"/>
                    <measurement group_id="O3" value="636" lower_limit="561" upper_limit="722"/>
                    <measurement group_id="O4" value="1298" lower_limit="1151" upper_limit="1464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 Post-dose 3 (N = 309, 309, 307, 312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1190" lower_limit="1054" upper_limit="1344"/>
                    <measurement group_id="O2" value="1232" lower_limit="1101" upper_limit="1379"/>
                    <measurement group_id="O3" value="1120" lower_limit="994" upper_limit="1261"/>
                    <measurement group_id="O4" value="1981" lower_limit="1756" upper_limit="2234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 Post-dose 3 (N = 310, 309, 307, 312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1102" lower_limit="972" upper_limit="1250"/>
                    <measurement group_id="O2" value="1119" lower_limit="975" upper_limit="1284"/>
                    <measurement group_id="O3" value="1097" lower_limit="963" upper_limit="1250"/>
                    <measurement group_id="O4" value="1944" lower_limit="1680" upper_limit="2249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Post-dose 3 (N = 312, 310, 312, 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" lower_limit="2.80" upper_limit="4.05"/>
                    <measurement group_id="O2" value="4.02" lower_limit="3.35" upper_limit="4.82"/>
                    <measurement group_id="O3" value="3.33" lower_limit="2.72" upper_limit="4.07"/>
                    <measurement group_id="O4" value="2.24" lower_limit="1.90" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting at Least One Solicited Injection Site (Study Vaccine) or Systemic Reactions After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccine</title>
        <description>Solicited Injection Site Reactions: Pain, Erythema, and Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia,and Irritability. Grade 3 was defined as: Pain, cries when injected limb is moved or movement of the limb is reduced; Erythema and Swelling, ≥ 5 cm; Pyrexia, (Temperature) ≥ 39.6°C; Vomiting, ≥ 6 episodes/24 hours or requiring parenteral hydration; Crying, &gt; 3 hours; Somnolence, sleeping most of time or difficult to wake up; Anorexia, refuses ≥ 3 feed/meals or refuses most feeds/meals; and Irritability, inconsolable.</description>
        <time_frame>Day 0 up to 7 after each dose</time_frame>
        <population>Solicited injection site and systemic reactions were assessed in all participants who received at least one dose of study vaccine (Safety Analysis Set).</population>
        <group_list>
          <group group_id="O1">
            <title>DTap-IPV-Hep B-PRP~T Batch A</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch A of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-Hep B-PRP~T Batch B</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch B of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-Hep B-PRP~T Batch C</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch C of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa</title>
            <description>Participants received a 3-dose primary series of vaccinations with the licensed Infanrix hexa™, with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Solicited Injection Site (Study Vaccine) or Systemic Reactions After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccine</title>
          <description>Solicited Injection Site Reactions: Pain, Erythema, and Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia,and Irritability. Grade 3 was defined as: Pain, cries when injected limb is moved or movement of the limb is reduced; Erythema and Swelling, ≥ 5 cm; Pyrexia, (Temperature) ≥ 39.6°C; Vomiting, ≥ 6 episodes/24 hours or requiring parenteral hydration; Crying, &gt; 3 hours; Somnolence, sleeping most of time or difficult to wake up; Anorexia, refuses ≥ 3 feed/meals or refuses most feeds/meals; and Irritability, inconsolable.</description>
          <population>Solicited injection site and systemic reactions were assessed in all participants who received at least one dose of study vaccine (Safety Analysis Set).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="345"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="342"/>
                <count group_id="O4" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain Post-dose 1 (N = 338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="194"/>
                    <measurement group_id="O3" value="216"/>
                    <measurement group_id="O4" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Post-dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="196"/>
                    <measurement group_id="O3" value="203"/>
                    <measurement group_id="O4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Post-dose 3 (N = 331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="162"/>
                    <measurement group_id="O4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain Post Dose 1 (N = 338, 341, 344, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain Post Dose 3 (N=331, 331, 334, 338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-dose 1 (N = 338, 341, 340, 344</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-dose 2 (N = 333, 337, 335, 340</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-dose 3 (N = 331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema Post-dose 1(N=338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema Post-dose 3(N=331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post dose 1 (N = 338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post dose 3 (N = 331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling Post-dose 1(N=338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling post-dose 3(N=331, 331, 340, 338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia Post dose 1 (N = 338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia Post dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia Post dose 3 (N = 331, 331, 333, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pyrexia Post-dose 1 (N=338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pyrexia Post-dose 3 (N=331, 331, 333, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Post dose 1 (N = 338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Post dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Post dose 3 (N = 331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting Post-dose 1(N=338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting post-dose 3(N=331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying Post dose 1 (N = 338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="186"/>
                    <measurement group_id="O3" value="189"/>
                    <measurement group_id="O4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying Post dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="179"/>
                    <measurement group_id="O3" value="169"/>
                    <measurement group_id="O4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying Post dose 3 (N = 331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="145"/>
                    <measurement group_id="O3" value="142"/>
                    <measurement group_id="O4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Post-dose 1 (N =338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Post-dose 3 (N =331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence Post dose 1 (N = 338, 341, 341, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence Post dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="110"/>
                    <measurement group_id="O4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence Post dose 3 (N = 331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grad 3 Somnolence Post-dose 1 N=338, 341, 341, 344</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grad 3 Somnolence Post-dose 3 N=331, 331, 334, 337</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia Post dose 1 (N = 338, 341, 341, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia Post dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia Post dose 3 (N = 331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Anorexia Post-dose 1(N=338, 341, 341, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Anorexia Post-dose 3(N=331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability Post dose 1 (N = 338, 341, 341, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="206"/>
                    <measurement group_id="O3" value="208"/>
                    <measurement group_id="O4" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability Post dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="199"/>
                    <measurement group_id="O3" value="191"/>
                    <measurement group_id="O4" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability Post dose 3 (N = 331, 332, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="161"/>
                    <measurement group_id="O3" value="154"/>
                    <measurement group_id="O4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Irritability Post-dose 1N=338, 341, 341, 344</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Irritability Post-dose 3N=331, 332, 334, 337</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting at Least One Solicited Injection Site Reaction at the Prevenar Injection Site After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Vaccine</title>
        <description>Solicited Injection Site Reactions: Pain, Erythema, and Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability. Grade 3 was defined as: Pain, cries when injected limb is moved or movement of the limb is reduced; Erythema and Swelling, ≥ 5 cm; Pyrexia (Temperature), ≥ 39.6ºC; Vomiting, ≥ 6 episodes/24 hours or requiring parenteral hydration; Crying, &gt; 3 hours; Somnolence, sleeping most of time or difficult to wake up; Anorexia, refuses ≥ 3 feed/meals or refuses most feeds/meals; and Irritability, inconsolable.</description>
        <time_frame>Day 0 up to 7 post each vaccination</time_frame>
        <population>Solicited injection site and systemic reactions were assessed in all participants who received at least one dose of study vaccine (Safety Analysis Set).</population>
        <group_list>
          <group group_id="O1">
            <title>DTap-IPV-Hep B-PRP~T Batch A</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch A of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-Hep B-PRP~T Batch B</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch B of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-Hep B-PRP~T Batch C</title>
            <description>Participants received a 3-dose primary series of vaccinations with Batch C of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa</title>
            <description>Participants received a 3-dose primary series of vaccinations with the licensed Infanrix hexa™, with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Solicited Injection Site Reaction at the Prevenar Injection Site After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Vaccine</title>
          <description>Solicited Injection Site Reactions: Pain, Erythema, and Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, and Irritability. Grade 3 was defined as: Pain, cries when injected limb is moved or movement of the limb is reduced; Erythema and Swelling, ≥ 5 cm; Pyrexia (Temperature), ≥ 39.6ºC; Vomiting, ≥ 6 episodes/24 hours or requiring parenteral hydration; Crying, &gt; 3 hours; Somnolence, sleeping most of time or difficult to wake up; Anorexia, refuses ≥ 3 feed/meals or refuses most feeds/meals; and Irritability, inconsolable.</description>
          <population>Solicited injection site and systemic reactions were assessed in all participants who received at least one dose of study vaccine (Safety Analysis Set).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="345"/>
                <count group_id="O2" value="341"/>
                <count group_id="O3" value="342"/>
                <count group_id="O4" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain Post-dose 1 (N = 338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="184"/>
                    <measurement group_id="O4" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain Post-dose 1 (N = 338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Post-dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="183"/>
                    <measurement group_id="O3" value="180"/>
                    <measurement group_id="O4" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain Post-dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Post-dose 3 (N =331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="146"/>
                    <measurement group_id="O4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain Post-dose 3 (N = 331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-dose 1 (N = 338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema Post-dose 1 (N=338, 341, 340, 344</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema Post-dose 2 (N=333, 337, 335, 340</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-dose 3 (N = 331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema Post-dose 3 (N=331, 331, 334, 337</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post-dose 1 (N = 338, 341, 340, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling Post-dose 1 (N=338, 341, 340, 344</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post-dose 2 (N = 333, 337, 335, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling Post-dose 2 (N=333, 337, 335, 340</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post-dose 3 (N = 331, 331, 334, 337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling Post-dose 3 (N=331, 331, 334, 337</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from Day 0 after Dose 1 through up to 6 months after the last dose.</time_frame>
      <desc>A participant randomized to Batch B got the Batch A vaccine, safety analyses was according to the actual vaccine administered. Total number reported for each solicited event reflects those with available data for the indicated event.</desc>
      <group_list>
        <group group_id="E1">
          <title>DTap-IPV-Hep B-PRP~T Batch A</title>
          <description>Participants received a 3-dose primary series of vaccinations with Batch A of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
        <group group_id="E2">
          <title>DTaP-IPV-Hep B-PRP~T Batch B</title>
          <description>Participants received a 3-dose primary series of vaccinations with Batch B of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
        <group group_id="E3">
          <title>DTaP-IPV-Hep B-PRP~T Batch C</title>
          <description>Participants received a 3-dose primary series of vaccinations with Batch C of diphtheria, tetanus, pertussis (2-component acellular), recombinant hepatitis B (Hep B) Hansenula polymorpha and poliomyelitis vaccine adsorbed, and Haemophilus influenzae type b (Hib) vaccine [polyribosyl ribitol phosphate (PRP) conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T), with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
        <group group_id="E4">
          <title>Infanrix Hexa</title>
          <description>Participants received a 3-dose primary series of vaccinations with the licensed Infanrix hexa™, with one dose each at 2, 4, and 6 months of age. Prevenar™ was co-administered with study vaccine at 2, 4, and 6 months of age, and Rotarix™ was co-administered at 2 and 4 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="345"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="343"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="342"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Atrophy Congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sudden Infant Death Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="343"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="342"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Exanthema Subitum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Kawasaki's Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Otitis Media Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Periorbital Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="343"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="342"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia Primary Atypical</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia Viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="342"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Viral Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Asthmatic Crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Diaphragmatic Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Foreign Body Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="208" subjects_at_risk="345"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="343"/>
                <counts group_id="E3" subjects_affected="216" subjects_at_risk="342"/>
                <counts group_id="E4" subjects_affected="193" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="85" subjects_affected="85" subjects_at_risk="338"/>
                <counts group_id="E2" events="90" subjects_affected="90" subjects_at_risk="341"/>
                <counts group_id="E3" events="86" subjects_affected="86" subjects_at_risk="340"/>
                <counts group_id="E4" events="94" subjects_affected="94" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="87" subjects_affected="87" subjects_at_risk="338"/>
                <counts group_id="E2" events="79" subjects_affected="79" subjects_at_risk="341"/>
                <counts group_id="E3" events="96" subjects_affected="96" subjects_at_risk="340"/>
                <counts group_id="E4" events="68" subjects_affected="68" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="199" subjects_affected="199" subjects_at_risk="338"/>
                <counts group_id="E2" events="196" subjects_affected="196" subjects_at_risk="341"/>
                <counts group_id="E3" events="216" subjects_affected="216" subjects_at_risk="340"/>
                <counts group_id="E4" events="188" subjects_affected="188" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="338"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="341"/>
                <counts group_id="E3" events="48" subjects_affected="48" subjects_at_risk="340"/>
                <counts group_id="E4" events="44" subjects_affected="44" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="208" subjects_affected="208" subjects_at_risk="338"/>
                <counts group_id="E2" events="206" subjects_affected="206" subjects_at_risk="341"/>
                <counts group_id="E3" events="208" subjects_affected="208" subjects_at_risk="341"/>
                <counts group_id="E4" events="193" subjects_affected="193" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="70" subjects_affected="70" subjects_at_risk="338"/>
                <counts group_id="E2" events="68" subjects_affected="68" subjects_at_risk="341"/>
                <counts group_id="E3" events="72" subjects_affected="72" subjects_at_risk="340"/>
                <counts group_id="E4" events="70" subjects_affected="70" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="125" subjects_affected="99" subjects_at_risk="345"/>
                <counts group_id="E2" events="132" subjects_affected="96" subjects_at_risk="343"/>
                <counts group_id="E3" events="116" subjects_affected="90" subjects_at_risk="342"/>
                <counts group_id="E4" events="105" subjects_affected="87" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="75" subjects_affected="75" subjects_at_risk="338"/>
                <counts group_id="E2" events="97" subjects_affected="97" subjects_at_risk="341"/>
                <counts group_id="E3" events="96" subjects_affected="96" subjects_at_risk="341"/>
                <counts group_id="E4" events="75" subjects_affected="75" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="159" subjects_affected="159" subjects_at_risk="338"/>
                <counts group_id="E2" events="146" subjects_affected="146" subjects_at_risk="341"/>
                <counts group_id="E3" events="160" subjects_affected="160" subjects_at_risk="341"/>
                <counts group_id="E4" events="147" subjects_affected="147" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="198" subjects_affected="198" subjects_at_risk="338"/>
                <counts group_id="E2" events="186" subjects_affected="186" subjects_at_risk="341"/>
                <counts group_id="E3" events="189" subjects_affected="189" subjects_at_risk="340"/>
                <counts group_id="E4" events="161" subjects_affected="161" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="345"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="343"/>
                <counts group_id="E3" events="25" subjects_affected="23" subjects_at_risk="342"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

